We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals
VNDA

110 hedge funds and large institutions have $622M invested in Vanda Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 38 increasing their positions, 37 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

434% more call options, than puts

Call options by funds: $40.9M | Put options by funds: $7.66M

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

9% more capital invested

Capital invested by funds: $571M → $622M (+$51.2M)

4% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 23

3% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 37

1% more funds holding

Funds holding: 109 → 110 (+1)

Holders
110
Holders Change
+1
Holders Change %
+0.92%
% of All Funds
3.16%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.09%
New
24
Increased
38
Reduced
37
Closed
23
Calls
$40.9M
Puts
$7.66M
Net Calls
+$33.2M
Net Calls Change
-$10.4M

Top Buyers

Rank Fund Capital Flow
1
PC
Paulson & Co
New York
+$24.1M
2
SCA
Signpost Capital Advisors
New York
+$22.5M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$22.3M
4
KCM
Kingdon Capital Management
New York
+$7.81M
5
DM
Deerfield Management
New York
+$7.77M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$19.9M
2
BIM
Bogle Investment Management
Massachusetts
-$9.86M
3
AGA
Altrinsic Global Advisors
Connecticut
-$5.69M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$3.66M
5
TAM
THB Asset Management
Connecticut
-$3.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$3.1M +$20.8K +1,563 +0.8%
Macquarie Group
27
Macquarie Group
Australia
$2.91M -$1.33M -100,000 -36%
D.E. Shaw & Co
28
D.E. Shaw & Co
New York
$2.59M -$810K -60,850 -28%
SFM
29
Sphera Funds Management
Israel
$2.27M +$999K +75,000 +115%
SM
30
Sabby Management
Florida
$2.1M +$1.73M +130,000 New
GC
31
Guggenheim Capital
Illinois
$2.09M -$226K -16,992 -12%
Deutsche Bank
32
Deutsche Bank
Germany
$2.08M -$3.13M -235,173 -65%
Wellington Management Group
33
Wellington Management Group
Massachusetts
$2.04M – – –
CCM
34
Cupps Capital Management
Illinois
$2.01M +$1.66M +124,420 New
NCGI
35
Next Century Growth Investors
Minnesota
$1.97M +$1.62M +121,460 New
TD Asset Management
36
TD Asset Management
Ontario, Canada
$1.88M +$738K +55,400 +92%
SGAM
37
Smith Group Asset Management
Texas
$1.7M -$63.4K -4,763 -4%
JGC
38
J. Goldman & Co
New York
$1.68M +$1.38M +103,750 New
IHM
39
Iguana Healthcare Management
New York
$1.62M – – –
BIM
40
BlackRock Investment Management
Delaware
$1.59M +$86.2K +6,469 +7%
GS
41
Gagnon Securities
New York
$1.5M -$249K -18,680 -17%
Susquehanna International Group
42
Susquehanna International Group
Pennsylvania
$1.43M -$41.5K -3,119 -3%
California Public Employees Retirement System
43
California Public Employees Retirement System
California
$1.31M +$99.9K +7,500 +10%
BCM
44
Bridgeway Capital Management
Texas
$1.29M -$1.8M -134,792 -63%
WMSA
45
Weiss Multi-Strategy Advisers
New York
$1.21M +$355K +26,640 +55%
EI
46
EAM Investors
California
$1.07M +$878K +65,936 New
California State Teachers Retirement System (CalSTRS)
47
California State Teachers Retirement System (CalSTRS)
California
$1M +$20K +1,500 +2%
TA
48
Teachers Advisors
New York
$934K +$96.6K +7,252 +14%
AllianceBernstein
49
AllianceBernstein
Tennessee
$898K -$197K -14,813 -21%
JG
50
Jefferies Group
New York
$887K +$730K +54,843 New
1
2
3 4 5

VNDA Hedge Fund Activity: Q2 2014 in Review

110 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q2 2014, worth a combined $622M — up 9% from $571M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new VNDA positions and 23 closed out — a net gain of 1 holder — while 38 added to existing stakes and 37 trimmed.

The largest buyer was Paulson & Co, adding an estimated $24.1M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $19.9M sold.

  • 110 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q2 2014, up from 109 in Q1 2014.
  • Funds reported $622M of Vanda Pharmaceuticals stock for Q2 2014, up 9% quarter-over-quarter.
  • 24 funds opened new Vanda Pharmaceuticals positions in Q2 2014 and 23 closed out, a net change of +1 holder.
  • The largest Vanda Pharmaceuticals buyer in Q2 2014 was Paulson & Co, an estimated $24.1M added.
  • The largest Vanda Pharmaceuticals seller in Q2 2014 was Consonance Capital Management, an estimated $19.9M sold.

Based on aggregated 13F filings for Q2 2014.